Mutelo Luyando, Simutanda Cornelius, Muchaili Lweendo, Mweene Bislom C, Liweleya Situmbeko, Mulamfu Sydney, Chama Gift C, Siame Lukundo, Hamooya Benson M, Masenga Sepiso K
Department of Pathology and Microbiology, Mulungushi University, School of Medicine and Health Sciences, Livingstone, Zambia.
Department of Cardiovascular Science and Metabolic diseases, Livingstone Center for Prevention and Translational Science, Livingstone, Zambia.
PLoS One. 2025 Jul 14;20(7):e0328529. doi: 10.1371/journal.pone.0328529. eCollection 2025.
Microalbuminuria is a critical marker for early kidney damage and a predictor for proteinuria, a defining feature of renal disease. Its detection in high-risk individuals is vital for reducing the risk of adverse renal outcomes, particularly among persons living with diabetes, hypertension, and HIV. The evaluation of microalbuminuria in high-risk individuals allows for the early detection of renal impairment and the assessment of cardiovascular risk profiles. Additionally, it informs targeted therapeutic interventions and provides critical prognostic information, thereby enhancing overall clinical outcomes. The goal of the study was to determine the prevalence and correlates of microalbuminuria in high risk patients.
A cross-sectional study was conducted at Livingstone University Teaching Hospital (LUTH) from September 2023 to July 2024. We employed homogeneous purposive sampling to recruit 306 high-risk adults (≥18 years) with diabetes, hypertension, and/or HIV. Purposive sampling was employed to recruit patients attending routine medical clinic at LUTH. Sample size was calculated using the formula for a single proportion (expected prevalence: 30%, margin of error: 5%, 95% CI), yielding 323; we recruited 306 due to logistical constraints. Data were collected directly from participants as well as using hospital records and laboratory analysis of blood/urine samples. Descriptive and inferential statistics were analyzed using SPSS v22.
A total of 306 high-risk individuals were screened, with a median age of 46 years (IQR: 31-58). Of these, 61.8% (n = 189) were females and 38.2% (n = 117) were males. The prevalence of microalbuminuria was 28.8% (95%CI 23.7-33.8), while its prevalence among individuals with diabetes, hypertension, and HIV was 45.4%, 33.3%, and 39.1%, respectively. Microalbuminuria was significantly associated with diabetes (p = 0.033), individuals living with HIV (p = 0.035), and high-sensitivity C-reactive protein (Hs-CRP) (p = 0.007) in univariate analysis. On multivariable analysis, microalbuminuria was associated with diabetes (AOR 2.90; 95% CI 1.02-8.19 p = 0.044), Living with HIV (AOR 1.96; 95%CI 1.02-3.78; p = 0.042) and Hs-CRP (AOR 1.16; 95%CI 1.02-1.30 p = 0.015).
The findings underscore the importance of routine screening for microalbuminuria in high-risk populations. Early detection and intervention could prevent the progression of microalbuminuria to overt renal disease, particularly in individuals with diabetes, HIV, and systemic inflammation. Integrating microalbuminuria screening into chronic disease management programs is essential to mitigate renal complications in these vulnerable groups.
微量白蛋白尿是早期肾脏损伤的关键标志物,也是蛋白尿(肾脏疾病的一个决定性特征)的预测指标。在高危个体中检测微量白蛋白尿对于降低不良肾脏结局的风险至关重要,尤其是在糖尿病、高血压和艾滋病毒感染者中。对高危个体进行微量白蛋白尿评估有助于早期发现肾功能损害并评估心血管风险状况。此外,它为有针对性的治疗干预提供依据,并提供关键的预后信息,从而改善整体临床结局。本研究的目的是确定高危患者中微量白蛋白尿的患病率及其相关因素。
2023年9月至2024年7月在利文斯通大学教学医院(LUTH)进行了一项横断面研究。我们采用同质目的抽样法招募了306名患有糖尿病、高血压和/或艾滋病毒的高危成年人(≥18岁)。采用目的抽样法招募在LUTH常规门诊就诊的患者。使用单一比例公式(预期患病率:30%,误差幅度:5%,95%置信区间)计算样本量,得出323例;由于后勤限制,我们招募了306例。数据直接从参与者处收集,以及使用医院记录和血液/尿液样本的实验室分析。使用SPSS v22进行描述性和推断性统计分析。
共筛查了306名高危个体,中位年龄为46岁(四分位间距:31 - 58岁)。其中,61.8%(n = 189)为女性,38.2%(n = 117)为男性。微量白蛋白尿的患病率为28.8%(95%置信区间23.7 - 33.8),而在糖尿病、高血压和艾滋病毒感染者中的患病率分别为45.4%、33.3%和39.1%。在单变量分析中,微量白蛋白尿与糖尿病(p = 0.033)、艾滋病毒感染者(p = 0.035)和高敏C反应蛋白(Hs - CRP)(p = 0.007)显著相关。在多变量分析中,微量白蛋白尿与糖尿病(调整后比值比2.90;95%置信区间1.02 - 8.19;p = 0.044)、感染艾滋病毒(调整后比值比1.96;95%置信区间1.02 - 3.78;p = 0.042)和Hs - CRP(调整后比值比1.16;95%置信区间1.02 - 1.30;p = 0.015)相关。
研究结果强调了在高危人群中常规筛查微量白蛋白尿的重要性。早期发现和干预可以预防微量白蛋白尿进展为显性肾脏疾病,尤其是在糖尿病、艾滋病毒感染者和全身性炎症患者中。将微量白蛋白尿筛查纳入慢性病管理计划对于减轻这些弱势群体的肾脏并发症至关重要。